Design of a novel class of biphenyl CETP inhibitors

被引：15

作者：

Lu, Zhijian ^{[1
]}

Napolitano, Joann B. ^{[1
]}

Theberge, Ashleigh ^{[1
]}

Ali, Amjad ^{[1
]}

Hammond, Milton L. ^{[1
]}

Tan, Eugene ^{[1
]}

Tong, Xinchun ^{[1
]}

Xu, Suoyu S. ^{[1
]}

Latham, Melanie J. ^{[2
]}

Peterson, Laurence B. ^{[2
]}

Anderson, Matt S. ^{[3
]}

Eveland, Suzanne S. ^{[3
]}

Guo, Qiu ^{[3
]}

Hyland, Sheryl A. ^{[3
]}

Milot, Denise P. ^{[3
]}

Chen, Ying ^{[3
]}

Sparrow, Carl P. ^{[3
]}

Wright, Samuel D. ^{[3
]}

Sinclair, Peter J. ^{[1
]}

机构：

[1] Merck Sharp & Dohme Corp, Dept Med Chem, Rahway, NJ 07065 USA

[2] Merck Sharp & Dohme Corp, Dept Pharmacol, Rahway, NJ 07065 USA

[3] Merck Sharp & Dohme Corp, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 24期

关键词：

CETP inhibitors; HDL-C; Biphenyl; ESTER TRANSFER PROTEIN; HIGH-DENSITY-LIPOPROTEIN; TORCETRAPIB; CORONARY; CHOLESTEROL; POTENT; HDL; NIACIN; RISK; 2-ARYLBENZOXAZOLES;

D O I：

10.1016/j.bmcl.2010.10.019

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A new class of CETP inhibitors was designed and prepared. These compounds are potent both in vitro and in vivo. The most active compound (12d) has shown an ability to raise HDL significantly in transgenic mouse PD model. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：7469 / 7472

页数：4

共 46 条

[1]

Athyros VG, 2008, EXPERT OPIN INV DRUG, V17, P445, DOI [10.1517/13543784.17.4.445, 10.1517/13543784.17.4.445 ]

[2] Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[3] Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [J].

Brown, BG ;

Zhao, XQ ;

Chait, A ;

Fisher, LD ;

Cheung, MC ;

Morse, JS ;

Dowdy, AA ;

Marino, EK ;

Bolson, EL ;

Alaupovic, P ;

Frohlich, J ;

Albers, JJ ;

Serafini, L ;

Huss-Frechette, E ;

Wang, S ;

DeAngelis, D ;

Dodek, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) :1583-1592

[4] Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].

Cannon, CP ;

Braunwald, E ;

McCabe, CH ;

Rader, DJ ;

Rouleau, JL ;

Belder, R ;

Joyal, SV ;

Hill, KA ;

Pfeffer, MA ;

Skene, AM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504

[5]

CAO G, 2005, Patent No. 05037796

[6] Raising high-density lipoprotein with chollesteryll ester transfer protein inhibitors [J].

Clark, RW .

CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (02) :162-168

[7] Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib [J].

Clark, RW ;

Sutfin, TA ;

Ruggeri, RB ;

Willauer, AT ;

Sugarman, ED ;

Magnus-Aryitey, G ;

Cosgrove, PG ;

Sand, TM ;

Wester, RT ;

Williams, JA ;

Perlman, ME ;

Bamberger, MJ .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (03) :490-497

[8]

CUCHEL M, 2007, J AM COLL CARDIOL, V1956, P50

[9] CETP inhibition [J].

Duriez, Patrick .

LANCET, 2007, 370 (9603) :1882-1883

[10] Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors [J].

Eary, C. Todd ;

Jones, Zachary S. ;

Groneberg, Robert D. ;

Burgess, Laurence E. ;

Mareska, David A. ;

Drew, Mark D. ;

Blake, James F. ;

Laird, Ellen R. ;

Balachari, Devan ;

O'Sullivan, Michael ;

Allen, Andrew ;

Marsh, Vivienne .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (09) :2608-2613

← 1 2 3 4 5 →